Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Seloken ZOK/Toprol-XL · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Seloken ZOK/Toprol-XL | DRUG | 50 mg |
| Placebo | DRUG | - |
Inclusion Criteria: * Diagnosis of stable asymptomatic heart failure. * Documented ejection fraction less than 0.40. * Must be able to comply with all study procedures. Exclusion Criteria: * Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization. * Have heart proble...
Seloken ZOK/Toprol-XL is used for congestive heart failure. It is a small molecule cardiovascular drug being developed by AstraZeneca PLC. The drug is currently in Phase 3 clinical development for this indication.
Seloken ZOK/Toprol-XL is a small molecule cardiovascular drug. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being studied for its effects on congestive heart failure.
Seloken ZOK/Toprol-XL is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the drug for congestive heart failure.
Seloken ZOK/Toprol-XL is in Phase 3 clinical development. It is an investigational drug being studied for congestive heart failure and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Seloken ZOK/Toprol-XL has one completed Phase 3 clinical trial, identified as NCT00038077, titled "Reversal of Ventricular Remodeling With Toprol-XL." The trial enrolled 300 participants with congestive heart failure in the United States and was randomized and double-blind.
Yes, Seloken ZOK/Toprol-XL is also known as Toprol-XL. The clinical trial NCT00038077 refers to the drug as Toprol-XL, and it is being studied for congestive heart failure by AstraZeneca PLC.